H.C. Wainwright lowered the firm’s price target on Biomea Fusion (BMEA) to $18 from $40 and keeps a Buy rating on the shares following the Q1 report. The firm removed removing type 1 diabetes from its projections and purged out the projected launch years for icovamenib in type 2 to 2031 from 2029.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMEA:
- Biomea Fusion reports Q1 EPS (80c), consensus (60c)
- Biomea Fusion price target lowered to $3 from $11 at Barclays
- Biomea Fusion’s Strategic Shift: A Year of Transformation
- Biomea Fusion reports Q4 EPS (81c), consensus (93c)
- Buy Rating for Biomea Fusion’s Icovamenib: A Promising Breakthrough in Diabetes Treatment
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue